Clinical trials: Antipsychotic Agents
Schizophrenia and Related Disorders, Drug Administration Schedule
"Extended" (Alternate Day) Antipsychotic Dosing
The study wishes to examine whether "extended" antipsychotic treatment, in this case, antipsychotic treatment every other day, is as effective as daily treatment.
- Conditions
- Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy, Antipsychotic Agents
- Trial name
- NCT04478838
- Testing
- Risperidone, Olanzapine, paliperidone
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
Antipsychotic Medication Extended Dosing Study
In patients stabilized on their antipsychotic and demonstrating evidence of good clinical response, there will not be a significant change in symptoms if their medication is decreased to every 2 days rather than daily.
- Trial name
- NCT00431574
- Testing
- dosing
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Metabolic Syndrome X
Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome
The investigators developed an easy identification model to identify metabolic syndrome in patients with schizophrenia or schizoaffective disorder who received treatment of clozapine, olanzapine, or risperidone.
- Trial name
- NCT00956189
- Testing
- amisulpride, aripiprazole
- Where
- 3 sites in Taiwan
- Volunteers
- 132 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
The purpose of this study is to evaluate the long-term treatment efficacy, and safety of risperidone long-acting injection in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01894984
- Testing
- Risperidone, Oral atypical anti-psychotic
- Volunteers
- 640 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment of depressive symptoms.
- Trial name
- NCT00159757
- Testing
- ziprazidone
- Where
- 8 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Antipsychotic Effects of Oxytocin
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with…
- Trial name
- NCT01621737
- Testing
- Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of California, San Diego
Schizophrenia
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated with aripiprazole once-monthly as per normal clinical practice at least 6 months before the data…
- Trial name
- DOMINO (NCT03005769)
- Where
- 20 sites in Italy
- Volunteers
- 262 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
- Trial name
- NCT05654870
- Testing
- Valbenazine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Neurocrine Biosciences
Weight, Body
Long-term Antipsychotic Pediatric Safety Trial
Main LAP01 study: The purpose is to evaluate the long-term pathologic weight changes associated with multi-year risperidone or aripiprazole therapy in 3 - <18-year-old children, who have varying durations of prior antipsychotic…
- Trial name
- LAPS (NCT03522168)
- Testing
- Risperidone, Aripiprazole
- Where
- 37 sites in United States
- Volunteers
- 509 people
- Sponsor
- Duke University
Drug-induced Extrapyramidal Side Effects
Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics
The project is aimed at addressing the fundamental issue in antipsychotic therapeutics -the balance between mental state benefits and neurological risks.The latter cannot be overestimated and clinical skills in themselves are…
- Trial name
- NCT02366897
- Testing
- Manus Sensor Pen
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Edinburgh
Schizophrenia
β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS
The purpose of this study is to determine whether atypical antipsychotic drugs (commonly prescribed for treating schizophrenia) induce changes in anthropometry and metabolism, including alteration in insulin sensitivity and/or…
- Trial name
- SANAT (NCT00528359)
- Testing
- quetiapine or olanzapine or risperidone or aripiprazole
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Weight Gain
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
The purpose of this pilot study is to determine whether starting metformin in conjunction with a second-generation antipsychotic (SGA) and providing information about healthy eating and activity will prevent or reduce the amount…
- Trial name
- PREVENT (NCT00617240)
- Testing
- metformin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Tetrabenazine for Partial Responders
Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action…
- Trial name
- NCT00362804
- Testing
- Tetrabenazine
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
This study will compare employment support with behavioral skills training to employment support alone in schizophrenia patients taking either risperidone or olanzapine to determine which is more effective in helping the patients…
- Trial name
- NCT00183625
- Testing
- Individual Placement and Support (Supported Employment), Social Skills Training, Olanzapine
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia.
- Trial name
- NCT06179108
- Testing
- LB-102
- Where
- 25 sites in United States
- Volunteers
- 359 people
- Sponsor
- LB Pharmaceuticals Inc.
Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy
Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia
Functional dyspepsia (FD) is a common gastrointestinal disease, which is associated with decreased life quality and increased medical cost.
- Conditions
- Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy, Antipsychotic Drug
- Trial name
- NCT06756139
- Testing
- cognitive behavioural therapy mobile application, Flupentixol and Melitracen Tablets
- Where
- 7 sites in China
- Volunteers
- 88 people
- Sponsor
- Air Force Military Medical University, China